Cambridge, MA-based Forma Therapeutics has formed a partnership with the Leukemia & Lymphoma Society of White Plains, NY, to discover drugs for immune cell cancers, according to a press release. No financial details were revealed. The partnership will focus on blocking a protein known as “Bcl-6,” which plays a role many lymphomas. Forma has been on a roll on the fund-raising and partnership fronts, having revealed more than $50 million in funding last year as well as a drug-discovery deal with Lexington, MA-based Cubist Pharmaceuticals (NASDAQ:CBST).
By posting a comment, you agree to our terms and conditions.